- Home
- ATOS vs RFAI Comparison
ATOS vs RFAI Comparison
Compare ATOS & RFAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATOS
- RFAI
- Stock Information
- Founded
- ATOS 2009
- RFAI 2024
- Country
- ATOS United States
- RFAI Singapore
- Employees
- ATOS N/A
- RFAI N/A
- Industry
- ATOS Biotechnology: Pharmaceutical Preparations
- RFAI
- Sector
- ATOS Health Care
- RFAI
- Exchange
- ATOS Nasdaq
- RFAI NYSE
- Market Cap
- ATOS 140.9M
- RFAI 153.0M
- IPO Year
- ATOS 2012
- RFAI 2024
- Fundamental
- Price
- ATOS $0.96
- RFAI $10.19
- Analyst Decision
- ATOS Strong Buy
- RFAI
- Analyst Count
- ATOS 3
- RFAI 0
- Target Price
- ATOS $7.00
- RFAI N/A
- AVG Volume (30 Days)
- ATOS 952.6K
- RFAI 14.7K
- Earning Date
- ATOS 11-12-2024
- RFAI 01-01-0001
- Dividend Yield
- ATOS N/A
- RFAI N/A
- EPS Growth
- ATOS N/A
- RFAI N/A
- EPS
- ATOS N/A
- RFAI N/A
- Revenue
- ATOS N/A
- RFAI N/A
- Revenue This Year
- ATOS N/A
- RFAI N/A
- Revenue Next Year
- ATOS N/A
- RFAI N/A
- P/E Ratio
- ATOS N/A
- RFAI N/A
- Revenue Growth
- ATOS N/A
- RFAI N/A
- 52 Week Low
- ATOS $0.73
- RFAI $10.00
- 52 Week High
- ATOS $2.31
- RFAI $10.27
- Technical
- Relative Strength Index (RSI)
- ATOS 24.57
- RFAI N/A
- Support Level
- ATOS $1.17
- RFAI N/A
- Resistance Level
- ATOS $1.30
- RFAI N/A
- Average True Range (ATR)
- ATOS 0.08
- RFAI 0.00
- MACD
- ATOS -0.02
- RFAI 0.00
- Stochastic Oscillator
- ATOS 1.09
- RFAI 0.00
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary innovative medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.
About RFAI RF ACQUISITION CORP II
RF Acquisition Corp II is a blank check company.